Improvement of sustained virologic response (SVR) in the treatment of genotype 1 infected male patients with PEG-INFα-2b by ribavirin dose adjustments
S Mauss, E Zehnter, MP Manns, G Teuber, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, M Bilzer, G Tossing, D Hüppe · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background and Aims: Two peginterferon (weight-based PEG-INFα-2b and fixed-dose PEG-INFα-2a) and ribavirin regimens approved for HCV treatment were recently compared in the IDEAL study (McHutchison, 2009). While overall SVR rates of patients (pts) infected with genotype 1 (G1) were similar with both regimens a 10% difference was observed for pts weighing 75–85kg. The latter were treated either with PEG-INFα-2b plus 1000mg ribavirin (RBV)/d or PEG-INFα-2a plus 1200mg RBV/d suggesting RBV underdosage in the PEG2b regimen. In order to test this hypothesis we re-evaluated SVR rates of G1 pts treated in the German Pe…
